IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

John J Sapienza

USPTO Granted Patents = 38 

 

 

Average Co-Inventor Count = 12.1

ph-index = 14

Forward Citations = 552(Granted Patents)


Location History:

  • Chula Vista, CA (US) (2005 - 2023)
  • San Diego, CA (US) (2021 - 2024)

Company Filing History:

goldMedal25 out of 169 
 
Signal Pharmaceuticals, Inc.
 patents
silverMedal13 out of 549 
 
Celgene Corporation
 patents
bronzeMedal1 out of 52 
 
Pharmacopeia Drug Discovery, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...
Loading Chart...
Loading Chart...
38 patents (USPTO):
1. 12404241 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2025-09-02),
2. 12227490 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2025-02-18),
3. 12103920 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2024-10-01),
4. 11873283 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2024-01-16),
5. 11739075 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-08-29),
6. 11634407 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-04-25),
7. 11560371 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-01-24),
8. 11365184 - Antiproliferative compounds, and their pharmaceutical compositions and uses (2022-06-21),
9. 11325889 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2022-05-10),
10. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),
11. 11149007 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith (2021-10-19),
12. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),
13. 10618883 - Antiproliferative compounds, and their pharmaceutical compositions and uses (2020-04-14),
14. 10227325 - Antiproliferative compounds, and their pharmaceutical compositions and uses (2019-03-12),
15. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),

Title: The Innovative Journey of John J. Sapienza

Introduction: John J. Sapienza is an accomplished inventor based in San Diego, California, with an impressive portfolio of 36 patents to his name. His work primarily focuses on the development of novel compounds and methods related to medical treatment, showcasing a commitment to innovation in the pharmaceutical sector.

Latest Patents: Among his latest innovations are the Cereblon binding compounds and compositions, which provide promising avenues in treatment methodologies. He has also developed piperidine dione compounds, specifically the substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione structure, aimed at enhancing therapeutic applications.

Career Highlights: John has made significant contributions during his tenure at Signal Pharmaceuticals, Inc. and Celgene Corporation. His expertise in pharmaceutical research has been instrumental in driving forward innovative treatment solutions that benefit patients and the broader medical community.

Collaborations: Throughout his illustrious career, John has collaborated with notable professionals such as Patrick Papa and Deborah Mortensen. These collaborations have fostered an innovative environment, allowing for the exchange of ideas and the development of groundbreaking medical solutions.

Conclusion: John J. Sapienza's dedication to innovation and his remarkable achievements in the realm of pharmaceuticals highlight his important role as an inventor. His ongoing contributions continue to inspire future generations of innovators in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…